Small Molecule Discovery — High Content Suspension Cell Phenotypic Screening
What if you could phenotypically screen suspension cells at a fraction of the cost—and time—of a high-end, high-content imaging system?
As drug discovery teams turn back to phenotypic screening in the hopes of improving lead identification, high-content imaging (HCI) is becoming the method of choice for secondary compound screens and even primary screens with smaller, directed libraries. But these systems are optimized for adherent cells, leaving researchers focused on suspension cells (such as immune cells) with either low throughput methods such as flow cytometry and microscopy, or low-content methods such as plate readers. In addition, high-end HCI systems can be expensive, finicky, and complicated to use, with long per-plate data acquisition times.
The iQue Advanced Flow Cytometry platform is filling this gap by enabling high throughput, high-content screening of suspension cells. Easily screen large libraries formatted in 96-, 384- or 1536-well plates, generating rich, multi-readout data sets in a fraction of the time that a high-end, high-content imaging system takes. Get the data you need to prioritize compounds and move your discovery program into high gear with the iQue Advanced Flow Cytometry platform.
"In short, the iQue offers flow cytometry capabilities at real high throughput, making it the perfect instrument for cell and bead based screenings."
High-content screening comes to suspension cells with the iQue Advanced Flow Cytometry platform , all thanks to the patented air-gap-delimited sampling technology, sensitive flow cytometry detection engine, and intuitive ForeCyt® Software.
Faster than traditional flow
By sampling only microliters from each well, employing sophisticated automation, and rapidly delivering samples to the detectors, the iQue Advanced Flow Cytometry platform converts the low throughput, time consuming traditional flow cytometry approach into a truly high throughput method. Analyze 96-well plates as little as five minutes and 384-well plates in 20 minutes.
Saving money and speeding discovery
Because the iQue Advanced Flow Cytometry platform can sample as little as 1 µL from each well, assay volumes can be miniaturized down to 9 µL, saving reagent costs and conserving limited samples. The iQue3 HD (Blue-Red configuration) is the only flow-based format that is fully compatible with 1536-well plates. Custom order only. Contact your sales representative for availability.
Enabling high-content screening of suspension cells
While most high-content imaging systems are optimized for adherent cells, the flow-based technology of the iQue Advanced Flow Cytometry platform is optimized for suspension cells. Screen for immunomodulators using biologically relevant cells, or assess complex mixtures of cells (such as PBMCs) and generate data on each cell type at single-cell resolution.
Delivering powerful but easy-to-use decision-making tools
Purpose-built to manage large data sets from microtiter plates, ForeCyt Software includes data analysis and visualization tools with built-in standard curves and unique features such as Profile Map. Simplify dose-response analysis and streamline your compound prioritization workflow with the tools you need to make decisions from data.
Built with screeners in mind
With a number of prevalidated assay kits and consumables to save you time, enterprise-level ForeCyt Software for distributed data handling and analysis, and easy export to your electronic lab notebook system, iQue Advanced Flow Cytometry platform fits smoothly into your drug discovery workflows.
Accelerating phenotypic screening of suspension cells
- Perform high-content phenotypic screening on suspension cells.
- Gain insights fast for well-informed compound prioritization.
- Save on reagent costs and conserve limited samples.
- Streamline workflows with built-in data analysis tools and Electronic Lab Notebook (ELN) export capabilities.
Related Research
Small Molecule Screening: A Key Step in Drug Discovery
Drug development is a time-consuming and costly process. In the initial stages of discovery, scientists must identify several potential lead candidates, verify their mechanisms of action (MOA) against the target, and determine the optimal conditions for their production and functional activity.
With exceptional sensitivity, low baseline noise and drift, large injection volumes and novel unique gradient injection technologies, the Octet® SF3 SPR System offers unparalleled ease-of-use and throughput for drug discovery.
Generate high-quality binding kinetics and affinity data in a fraction of the time compared to standard multi-cycle or single-cycle kinetics.